메뉴 건너뛰기
Cancer
Volumn 117, Issue 6, 2011, Pages 1183-1189
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib
Author keywords

metastatic renal cell carcinoma; overall survival; progression free survival; sunitinib; tumor burden
Indexed keywords

BEVACIZUMAB; INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; SUNITINIB; SURAMIN; THALIDOMIDE; VOLOCIXIMAB;
EID: 79952373192     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25713     Document Type: Article
Times cited : (26)
References (13)
  • 5
    • 56749161699 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
    • Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26: 5422-5428.
    • (2008) J Clin Oncol. , vol.26 , pp. 5422-5428
    • Rini, B.I.1    Halabi, S.2    Rosenberg, J.E.3
  • 6
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • Sternberg CN, Davis I, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068.
    • (2010) J Clin Oncol. , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.2    Mardiak, J.3
  • 7
    • 34547108341 scopus 로고    scopus 로고
    • Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    • DOI 10.1002/cncr.22827
    • Choueri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007; 110: 543-550. (Pubitemid 47106142)
    • (2007) Cancer , vol.110 , Issue.3 , pp. 543-550
    • Choueiri, T.K.1    Garcia, J.A.2    Elson, P.3    Khasawneh, M.4    Usman, S.5    Golshayan, A.R.6    Baz, R.C.7    Wood, L.8    Rini, B.I.9    Bukowski, R.M.10
  • 8
    • 73349084973 scopus 로고    scopus 로고
    • Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study
    • Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794-5799.
    • (2009) J Clin Oncol. , vol.27 , pp. 5794-5799
    • Heng, D.Y.1    Xie, W.2    Regan, M.M.3
  • 9
    • 55049109179 scopus 로고    scopus 로고
    • Bevacizumab reduces the growth rate constants of renal carcinomas: A novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage
    • Stein WD, Yang J, Bates SE, Fojo T., Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist. 2008; 13: 1055-1062.
    • (2008) Oncologist. , vol.13 , pp. 1055-1062
    • Stein, W.D.1    Yang, J.2    Bates, S.E.3    Fojo, T.4
  • 10
    • 70350139039 scopus 로고    scopus 로고
    • Other paradigms: Growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma
    • Stein WD, Huang H, Menefee M, et al. Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma. Cancer J. 2009; 15: 441-447.
    • (2009) Cancer J. , vol.15 , pp. 441-447
    • Stein, W.D.1    Huang, H.2    Menefee, M.3
  • 11
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
    • (2000) J Natl Cancer Inst. , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 12
    • 55049137067 scopus 로고    scopus 로고
    • Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: A novel strategy for evaluation of clinical trial data
    • Stein WD, Figg WD, Dahut W, et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist. 2008; 13: 1046-1054.
    • (2008) Oncologist. , vol.13 , pp. 1046-1054
    • Stein, W.D.1    Figg, W.D.2    Dahut, W.3
  • 13
    • 77953341948 scopus 로고    scopus 로고
    • Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
    • Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol. 2010; 21: 936-941.
    • (2010) Ann Oncol. , vol.21 , pp. 936-941
    • Thiam, R.1    Fournier, L.S.2    Trinquart, L.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.